SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility amid allegations of a pump-and-dump scheme, sparking intense debate between traders labeling it a fraudulent manipulation and those betting on its potential through upcoming event-driven catalysts. While proponents point to real-world integration and event partnerships as drivers for growth, the community remains deeply polarized over concerns regarding highly concentrated supply ownership and the potential for a sudden, sharp decline.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a historical artifact of crypto culture, with investors highlighting its 2011 origin and recent tokenization as evidence of its enduring relevance. The community is actively debating its potential to reach billion-dollar market status, citing accumulation by high-net-worth wallets and the narrative strength of being the original parody of Bitcoin.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors digest a series of positive regulatory and clinical updates, including a significant executive order from the Trump administration aimed at accelerating FDA review processes for psychedelic-assisted therapies. Community sentiment is largely focused on the potential for reduced clinical timelines and the impact of upcoming late-stage trial readouts, fueling speculative volume and institutional interest in the broader psychedelic biotech sector.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is currently in the spotlight following the announcement of positive Phase 2 signal detection study results for its HLP004 anxiety therapeutic, even as investors grapple with significant volatility and the company's recent rebranding to the "HELP" ticker. Community discourse is sharply divided between long-term holders encouraged by institutional backing and a robust patent portfolio, and skeptical participants highlighting historical dilution concerns and the risks inherent in a clinical-stage biotech navigating a complex regulatory environment.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing a significant surge in momentum as the psychedelic biotech sector reacts to a new executive order that fast-tracks regulatory pathways for psychedelic-assisted therapies. Investors are actively debating the company's valuation, phase 3 clinical trial prospects, and its potential to be a high-premium buyout candidate, though sentiment remains divided between those betting on policy-driven breakthroughs and skeptics focused on historical volatility and cash burn concerns.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin (CRO) is seeing mixed community sentiment as investors debate the impact of ongoing token dilution against potential catalysts like a pending Cronos ETF and broader ecosystem expansion. While some users express frustration over the asset's price stagnation relative to Bitcoin, others are actively accumulating the coin, viewing the current range as a strategic entry point for long-term growth.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

The community is actively monitoring the Roundhill Ether Covered Call Strategy ETF for its consistent weekly dividend distributions, despite varied sentiment regarding the fund's net asset value performance. Investors are balancing the appeal of high-yield income strategies against the inherent volatility of the underlying Ethereum market as they track upcoming distribution announcements.

Daddy Darth Vader

The community is actively engaged in a rivalry known as the 'Daddy Wars' between $DARTH, $SIDIOUS, and $MAULCOIN, with discussions dominated by debates over developer transparency, liquidity strategies, and community-driven token giveaways. Participants are speculating on the next parabolic breakout while trading insults and tips regarding entry points in these highly volatile nano-cap assets.

Procure ETF Trust II - Procure Space ETF

The Procure Space ETF ($UFO) is attracting significant community attention as investors position themselves for the potential IPO of SpaceX and the broader expansion of the commercial space economy. While some community members appreciate the ETF for its broad exposure to industry leaders, others are debating whether its diverse holdings truly constitute a 'pure play' on space, leading to discussions about alternative investment strategies.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is seeing heightened investor attention as the community weighs potential revenue growth catalysts heading into next year, specifically the shift to CVS formulary coverage for Vevye and upcoming product launches. Discussion remains polarized between those focused on short-term technical volatility and short interest dynamics, and those emphasizing the long-term value of the expanding branded product portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
